

7 September 2016

Expansion of Involvement in Pharmaceutical Company's Clinical Trial

Resonance Health (ASX: RHT) today announced the extension of its involvement in a pharmaceutical company's Phase 3 clinical trial. A two year collaboration was announced in June 2016 for the provision of FerriScan and Cardiac T2* analysis services for the Asia-based component of the global trial. Resonance Health is delighted to extend our involvement in the clinical trial in two new directions. The first being a geographical extension to include a European-based country commencing participation in the study. The second noteworthy direction being the provision of a new additional service in the form of a Spleen Volume Measurement, to assist in the detection of hypersplenism.

Resonance Health specialises in the delivery of quantitative magnetic resonance imaging (MRI) techniques for the diagnosis and clinical management of human diseases. The Company currently offers three regulatory approved products; FerriScan® the globally recognised gold standard for quantitative measurement of liver iron concentration, HepaFat-Scan® for quantitative measurement of volumetric liver fat fraction (VLFF), and Cardiac T2* for assessment of heart iron loading. In the context of clinical studies and trials, Resonance Health is also able to perform Bone Marrow R2 measurement for iron assessment as well as iron, fat, and volumetric assessments in other organs.

General Manager of Resonance Health, Sander Bangma, commented:

"We pro-actively seek to add value and expand the services that we provide to the pharmaceutical companies who rely on Resonance Health's accurate, quantitative measurements in the efficacy testing of their investigational products. Our Research and Development efforts have focused on expanding our portfolio of products in addition to improving efficiencies of our existing operations. It is very rewarding to have successfully negotiated extension of the collaboration with our newest pharmaceutical company partner and to be commencing service delivery of our Spleen Volume Measurement."

FerriScan, Cardiac T2*, and now Spleen Volume Measurement will be provided for the Asia-based component and the new European-based country participating in the study; with service provision in Asia already underway. Research and Development and profiling efforts aim to continue to identify and bring to fruition further new service offerings for our pharmaceutical company partners, key opinion leader collaborators, and the clinical community alike.

For further information please contact:

Sander Bangma

General Manager, Resonance Health

E: SanderB@resonancehealth.com P: +61 (0)8 92845300

Resonance Health Ltd.

278 Stirling Hwy, Claremont, WA 6010, AUSTRALIA
www.resonancehealth.com

T + 61 8 9286 5300

Postal: PO Box 1135, Nedlands, WA, 6909, AUSTRALIA
info@resonancehealth.com